5 Key Takeaways
-
1
A 66-year-old man with Pi*ZZ alpha-1 antitrypsin deficiency received a single intravenous infusion of the investigational base-editing therapy YOLT-202.
-
2
Ten weeks after treatment, liver biopsy showed correction of 54% of targeted SERPINA1 alleles by Sanger sequencing and 57% by Illumina sequencing.
-
3
Testing found no detectable unintended editing at nearby DNA positions or predicted off-target sites.
-
4
Circulating alpha-1 antitrypsin rose from 0.15 g/L before treatment to 0.7 g/L at 10 weeks, and functional testing confirmed elastase inhibition.
-
5
Larger studies and longer follow-up are needed to determine whether the molecular improvements provide lasting protection against liver and lung disease.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
